Title: Transmission dynamics of *Klebsiella pneumoniae* in a neonatal intensive care unit in Zambia before and after an infection control bundle

Short title:
K. pneumoniae transmission in a neonatal ICU in Zambia

Authors:
Laura T Phillips [1,*], Matthew Bates [2,10] , Susan E Coffin [3,4], Ebenezer Foster-Nyarko [1], Monica Kapasa [5], Sylvia Machona [5], Lawrence Mwananyanda [6], James CL Mwansa [7], Chileshe L Musyani [8,9], John M Tembo [10], Franklyn N Egbe [11], Kathryn E Holt [1,12,#], Davidson H Hamer [13-15,#]

Affiliations:
[1] Department of Infection Biology, London School of Hygiene & Tropical Medicine, London, United Kingdom
[2] School of Natural Sciences, University of Lincoln, Lincoln, United Kingdom
[3] Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA
[4] Division of Infectious Diseases, Children's Hospital of Philadelphia, Philadelphia, PA, USA
[5] Women and Children's Hospital, University Teaching Hospital, Lusaka, Zambia
[6] Right to Care, Lusaka, Zambia
[7] Directorate of Research and Post Graduate Studies, Lusaka Apex Medical University, Lusaka, Zambia
[8] Institute of Basic and Biomedical Sciences, Levy Mwanawasa Medical University, Lusaka, Zambia
[9] Antimicrobial Resistance Unit, Zambia National Public Health Institute, Lusaka, Zambia
[10] HerpeZ, University Teaching Hospital, Lusaka, Zambia
[11] Institute of Infection, Veterinary & Ecological Sciences, University of Liverpool, Liverpool, United Kingdom
[12] Department of Infectious Diseases, School of Translational Medicine, Monash University, Melbourne, Victoria 3004, Australia
[13] Department of Global Health, Boston University School of Public Health, Boston, MA, USA
[14] Section of Infectious Diseases, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA
[15] Boston University Center on Emerging Infectious Diseases, Boston, MA, USA

[#] These authors contributed equally to this work

* Corresponding author:
Email: Laura.Phillips@lshtm.ac.uk

Abstract:

Background: *Klebsiella pneumoniae* is a leading cause of neonatal sepsis in low- and middle-income countries, with antimicrobial resistance (AMR) significantly contributing to associated mortality. Infection prevention and control (IPC) interventions effectively reduced healthcare-associated infections and significantly decreased neonatal mortality in the Sepsis Prevention in Neonates in Zambia (SPINZ) study. Here we use whole genome sequencing to explore the impact of an IPC intervention on *K. pneumoniae* strains and transmission dynamics responsible for sepsis in a Zambian neonatal unit.

Methods and Findings: Blood culture isolates were collected during the SPINZ study, including a 7-month baseline period and 12 months following implementation of a low-cost IPC bundle. Bacterial isolates were sequenced (using Illumina), assembled, and characterised in terms of lineage, AMR determinants, and polysaccharide antigens (using Kleborate and Kaptive). High-quality genome assemblies were obtained for 411 neonatal *K. pneumoniae* infections. The *K. pneumoniae* population was diverse, comprising 24 unique STs, but dominated by ST307 (69.3%, n=285). Nearly all isolates (99.0%) carried extended spectrum beta-lactamases, but few carried carbapenemases (2.7%). Probable transmission clusters were identified using single-linkage clustering with pairwise distance thresholds of ≤4 weeks and ≤10 single nucleotide variants (SNVs) between isolates. Most infections (95.6%) were associated with clusters, ranging in size from 2–202 patients and spanning durations of 2–232 days. Most *K. pneumoniae* (n=228, 70%) were isolated during the 7-month baseline period and formed six clusters, including one cluster of >200 neonates infected with ST307, which was interrupted by the IPC implementation. Novel clusters emerged during the post-intervention period, including additional STs and distinct ST307 lineages (unrelated to the pre-intervention cluster), but also ST2004 and ST101 clusters that were genetically indistinguishable from those detected pre-intervention.

Conclusions: In this neonatal unit, *K. pneumoniae* sepsis was mostly attributable to nosocomial transmission clusters, including a large and sustained outbreak of ST307 affecting >200 neonates over eight months. Transmission of all strains was periodically suppressed by an IPC bundle; however not all strains were eliminated, and some were able to re-emerge later to re-establish infection and transmission, alongside newly introduced strains that formed additional transmission clusters. Some clusters were associated with rapid onset of disease (within 2 days of admission) and others with delayed onset, suggesting different sources of contamination (e.g. reagent vs environmental). These findings reinforce the need for sustained IPC efforts, and better understanding of environmental reservoirs of opportunistic pathogens in neonatal units to inform such efforts.

Introduction

In 2019, an estimated 2.44 million neonatal deaths were attributable to infectious causes (1), with 99% of these deaths occurring in low- and middle-income countries (LMICs) (2). Neonatal sepsis in LMICs contributes significantly to this high burden of neonatal deaths, accounting for 78.9% of the world's total reported cases and 93.9% of global neonatal deaths in 2019 (3-5). *Klebsiella* species, predominantly *Klebsiella pneumoniae*, are a leading agent of neonatal sepsis (4, 6), with infections additionally often resistant to World Health Organization (WHO) recommended treatment regimens (7). It is estimated that the fraction of sepsis deaths attributable to antimicrobial resistance (AMR) increased by 18% in children younger than 5 years between 1990 to 2019, with *K. pneumoniae* being one of the biggest contributors to AMR-attributable sepsis deaths in 2021 (8, 9). Of particular concern is the increasing proportion of neonatal deaths attributable to extended-spectrum beta-lactamase (ESBL) producing or carbapenem-resistant *K. pneumoniae*, which was declared a critical priority in the WHO Bacterial Priority Pathogen List (8, 10).

Accurate and timely diagnosis of neonatal sepsis in LMICs is challenging, due to shared clinical features with many common conditions, and neonates not consistently presenting with severe clinical signs (11, 12). Additionally, limited availability of blood culture and other laboratory testing may limit accurate and prompt diagnosis, ultimately leading to underestimation of the burden of neonatal sepsis (12).

Given the prevalence of AMR among *Klebsiella* isolates, the growing burden of *K. pneumoniae* related sepsis, and the diagnostic challenges, there is a renewed focus on prevention. A significant measure proposed to reduce the burden of neonatal sepsis is the introduction of a maternal vaccine, targeting the external capsular (K) and/or lipopolysaccharide (O) antigens of *K. pneumoniae* (13, 14). Pathogen-agnostic prevention measures, such as infection prevention and control (IPC) interventions within neonatal intensive care units (NICUs), are more realistic and achievable in the short-term, with some having been shown to be effective in reducing infection and mortality. However, the evidence base is limited, and the relative efficacy of different intervention strategies is not yet clear (15-18).

The impact of prevention strategies on pathogen populations can be informed by pathogen whole genome sequencing (WGS). Evaluations of IPC interventions measure key outcomes such as the number of infections and fatalities; however, pathogen WGS can be additionally used to enhance our understanding of the underlying bacterial populations targeted by the intervention, how they change in response to the intervention, and whether changes are stable over the duration of the intervention (19). In the absence of serological K typing, which is only available in one centre globally, WGS is also the predominant tool for profiling K and O serotypes in *K. pneumoniae* (20, 21).

We recently reported an evaluation of an IPC intervention in a NICU in Zambia, where the majority of positive blood cultures (>70%) yielded *K. pneumoniae* (22). The multi-faceted intervention included IPC training, text message reminders, alcohol hand rub, enhanced environmental cleaning, and weekly bathing of babies ≥1.5 kg with 2% chlorhexidine gluconate. Mortality decreased following the

implementation of these measures compared with the pre-intervention (baseline) period of observation (22). Here we use WGS to characterize stored *K. pneumoniae* clinical isolates from that study, to compare the populations before and after the IPC intervention and investigate its impact on the pathogen population.

Methods

Ethics

The Sepsis Prevention in Neonates in Zambia (SPINZ) study was reviewed and approved by the institutional review boards and ethics boards at Boston University, Children's Hospital of Philadelphia, and the Excellence in Research Ethics and Science (ERES) Converge in Zambia. Written informed consent was provided by the mothers of neonates recruited into the study. Retrospective investigation of transmission using WGS was also approved by the Observational/Interventions Research Ethics Committee of the London School of Hygiene and Tropical Medicine (ref #29931).

Study population

SPINZ was a prospective observational cohort study of hospitalized neonates conducted in a large tertiary care University Teaching Hospital (UTH) in Lusaka, Zambia. Full details of the original intervention study were reported previously (22). Briefly, a 6-month baseline period ('Baseline'), was followed by six weeks of IPC bundle implementation and 11 months of intervention assessment, both combined in this study to be referred to as the 'Post-implementation' period. During SPINZ, neonates admitted to the NICU between September 2015, and March 2017 were enrolled in the prospective study, and blood cultures were obtained from all neonates with clinically suspected sepsis (defined as fever, hypothermia, tachycardia or bradycardia, hypoglycemia, respiratory difficulty, new-onset seizures, lethargy, poor feeding, abdominal distention, vomiting, diarrhea, or poor perfusion) (23). The NICU has approximately 3300 admissions per year and is typically filled beyond its official capacity (60 cots and an average daily count of 75 infants). Blood culture was performed at the UTH microbiology laboratory, Lusaka, Zambia using BD Bactec FX200 culture system (BD Life Sciences, New Jersey, USA), followed by species identification and antibiotic susceptibility testing with the automated Vitek 2 Compact system (bioMérieux, Marcy-l'Étoile, France). Isolates were stored in Skim milk-tryptone-glucose-glycerine stocks at -80° until further processing.

Bacterial isolates, sequencing and sequence analysis

All blood culture isolates from SPINZ that were identified as *Klebsiella* or *E. coli* were retrieved and revived in preparation for WGS. Frozen bacterial glycerol stocks were revived by streaking onto LB agar plates and incubating overnight at 37°C. A single colony pick was taken from each plate to inoculate LB broth and incubated overnight at 37°C. All procedures were performed under sterile conditions using aseptic techniques. DNA was extracted using the QIAamp DNA Mini Kit (QIAgen, Hilden, Germany), and shipped to the Quadram Institute of Bioscience, UK for sequencing.

Libraries were generated using a modified Nextera XT DNA protocol (24) and sequenced on an Illumina NextSeq 500 instrument (Illumina, California, USA).

Paired-end reads were de-novo assembled using Unicycler v0.5.0 (23) (depth filter: 0, mode: normal). Assemblies were filtered based on the KlebNET-GSP quality control criteria (i.e. contig count <500, genome size in the range 4,969,898 to 6,132,846 bp, and G+C content 56.35% to 57.98%). Assemblies meeting these criteria were uploaded to Pathogenwatch (25), and those not confirmed as *K. pneumoniae* species (n=32), were excluded from further analysis. Only the first WGS-confirmed *K. pneumoniae* isolate per neonate was included, thus excluding n=2 assemblies.

Genome assemblies were further analysed using Kleborate v3.1.3 (26) to identify multi-locus sequence types (STs) and to determine the presence of AMR determinants. K and O loci (gene clusters encoding the capsule or lipopolysaccharide, respectively), and the associated K and O serotype predictions, were identified using Kaptive v3.1.0 (20). Pathogenwatch was used to generate pairwise distances and a neighbour-joining tree of all *K. pneumoniae* genomes (based on 1,972 core genes (25)).

WGS data were matched to clinical metadata including sex, clinical outcome (discharged or death), date of NICU admission, date of specimen collection, and birth location.

For STs represented by at least four genomes, we undertook phylogenetic and transmission analysis. For each ST, the closest reference sequence to our isolates was identified using Bactinspector closest_match (v0.1.3) (27) (*K. pneumoniae* genomes updated from NCBI prior to running, June 2024). Accession numbers for all reference sequences are provided in **Supplementary Table S1.**

Snippy (v4.4.5) (28) was used to identify single nucleotide variants (SNVs) against the reference genome for each ST. The Coresnpfilter (v0.2.0) (29) package was used with a threshold of 80% (-c 0.8), to generate an alignment of all variant sites with an allele called in at least 80% of sequences. Invariant sites were included to create a final pseudo whole-genome alignment containing high-quality SNVs. Each alignment was filtered for recombination using Gubbins (v3.3.5) (30), and maximum-likelihood phylogenetic trees inferred from the resulting recombination-filtered alignment using RAxML-NG (v8.2.13) (31), with the GTR+G model and 1000 bootstrap repeats. The final bootstrapped tree was midpoint rooted using ggtree (v3.12.0) (32).

Transmission clusters were identified using the Transmission Estimator tool (33) taking as input a pairwise SNV distance matrix (generated for each ST from the recombination-filtered alignment, using snp-dists (v0.6.3) and pairwise temporal distances between infection dates (culture date where available, otherwise NICU admission date). Clustering via single-linkage with thresholds of 7–28 days and 5–25 SNVs, were tested. Only isolates with an available infection date were included in transmission/clustering analysis (148 isolates excluded).

In all genomes, contigs were investigated for plasmid indicators using the MOB-suite package (v3.1.9) (34). Plasmids were classified into clusters, with clustered plasmids sharing the same generated ID across isolates. Novel plasmids were determined if the genomic distance deviated by >0.05 from a known reference. The tool Abricate (v1.0.1) (35) was used to detect the presence of AMR genes (using the CARD database (36)) on plasmids identified by MOB-suite.

To investigate *mphA* plasmids in ST307 clusters, we used the Bandage assembly graph viewer (v0.8) (37) to assess the plausibility of the nearest neighbour reference plasmid identified by MOB-suite being the location of the *mph*A gene. We used the blastn function in Bandage to search each graph for the reference plasmid sequence and the *mph*A gene, using the blastn parameter '-max_hsps 1' to report non-overlapping hits which we summed to calculate overall coverage and mean identity of the reference plasmid in each assembly.

Statistical analysis

All statistical analyses were carried out in R (v4.4.0). The number of days to infection onset relative to admission was calculated for neonates with both a known date of NICU admission and culture date. This variable was categorised into 0 days through to 7 days, 8+ days and unknown, and into 'rapid-onset' (days 0–2) and 'delayed-onset' (days 3+) categories for comparison and ease of visualisation. Location of birth was categorized into 'inborn' if the neonate was born in any UTH site (including the UTH labour ward, UTH theatre and UTH postnatal wards), and 'outborn' for any other birth location. Study month was categorised into baseline and post-implementation, month 1–7 vs month 8–17, respectively.

Categorical variables with more than two groups were compared using the Kruskal–Wallis test. For binary variables, comparisons were conducted using the chi-squared test or Fisher's exact test when expected cell counts were small (<5). Differences in proportions (i.e., probabilities of success) across groups were assessed using the prop.test function from the *stats* package (v4.4.0). Univariate logistic regression was used to evaluate the association between birth location (inborn vs outborn) or onset category (rapid-onset vs delayed-onset) and cluster membership, using the glm() function (family=binomial) from the *stats* package. In all cases, a significant difference was considered if the p-value was <0.05.

Code and data availability

All analysis and visualisation code are available at https://github.com/klebgenomics/SPINZ (DOI: 10.5281/zenodo.17589084).

Whole-genome sequence data were deposited by the sequencing laboratory (Quadram Institute of Bioscience, UK) under BioProject PRJEB33565. Sample level accession information, together with associated clinical and source data, and WGS-derived typing data, is provided in **Supplementary Table S2.**

Results

Of 465 blood culture isolates identified as *Klebsiella* species during the study period, 460 were successfully sequenced and 443 of these were confirmed from WGS as *K. pneumoniae*. Two isolates originally identified as *E. coli* were additionally characterised as *K. pneumoniae* from WGS data. Thus, we confirmed 445 blood-culture positive *K. pneumoniae* infections. Following quality control, a total of 411 confirmed high-quality *K. pneumoniae* genomes remained representing unique neonatal infections (**S1 Figure**). Twenty-four different *K. pneumoniae* STs were identified (**Table 1**).

295 **Table 1: K and O loci and types identified per ST**

ST	K locus	K type	O locus	O type	Count
ST307 (n=285)	KL102	Capsule null (n=249)	OL2α.2	O2β	193
			OL2α.2	O2α	56
		Unknown (n=36)	OL2α.2	O2β	36
ST2004	KL23	K23	OL2α.2	O2β	58
ST983	KL127	Unknown	OL13	O13	12
ST5856	KL15	K15	OL4	O4	9
ST101	KL17	K17	OL2α.1	O1αβ,2α	9
ST985	KL39	K39	OL2α.2	O1αβ,2β	6
ST15	KL54	K54	OL2α.2	O1αβ,2β	4
ST147	KL64	K64	OL2α.1	O2α	4
ST1119	KL110	Unknown	OL3γ	O3γ	4
ST1486	KL38	K38	OL3γ	O3γ	3
ST340	KL15	K15	OL4	O4	2
ST268	KL20	K20	OL2α.1	O2α	2
ST45	KL24	K24	OL2α.1	O2α	2
ST14	KL2	K2	OL2α.1	O1αβ,2α	1
ST1427	KL67	K67	OL13	O13	1
ST13	KL3	K3	OL2α.2	O1αβ,2β	1
ST1731	KL122	Unknown	OL2α.2	O2β	1
ST20	KL24	K24	OL2α.1	O1αβ,2α	1
ST253	KL64	K64	OL2α.1	O1αβ,2α	1
ST280	KL23	K23	OL2α.2	O2β	1
ST405	KL151	Unknown	OL4	O4	1
ST54	KL14	K14	OL3γ	O3γ	1
ST831	KL18	K18	OL2α.1	O1αβ,2α	1
ST966	KL71	K71	OL3γ	O3γ	1

296

297 The most prevalent was ST307 (69.3%, 285/411), followed by ST2004 (14.1%,
298 58/411). In total, there were nine common STs, each represented by ≥4 infection
299 isolates. There was a close association between K locus and ST, with each ST
300 associated with a single K locus. KL102 was the most commonly identified K locus,
301 exclusively found in all ST307 isolates (**Table 1**). The second most prevalent was
302 KL23, found in all ST2004 isolates. The most prevalent O type was O2, representing
303 72.3% (297/411) of isolates (**Table 1**). Each ST was associated with a single O type,
304 except for ST307 in which 19.6% (n=56/285) of isolates were O2α and the remainder
305 O2β (n=229/285).
306
307 The presence and number of acquired AMR genes varied between and within STs
308 (**Figure 1**). Few isolates had an acquired carbapenemase gene (n=11/411, 2.7%; all
309 ST5856 or ST340 carrying bla_{NDM-5}). Most isolates had an acquired extended-
310 spectrum ß-lactamase (ESBL) gene (99.0%, 407/411; n=405 with only $bla_{CTX-M-15}$ in
311 22 STs, n=1 ST5856 with both $bla_{CTX-M-15}$ and $bla_{TEM-116}$, n=1 ST101 with $bla_{CTX-M-14}$).
312 Many isolates had additional acquired AMR genes detected, including those
313 associated with resistance to ß-lactams (bla_{OXA-1} and bla_{TEM-1}, 99.3%; supplementing
314 the intrinsic core gene bla_{SHV}), fluoroquinolones (81.5%), aminoglycosides (100%),
315 tetracycline (75.7%), phenicols (12.9%), macrolides (10.7%), sulfonamides (99.5%)
316 or trimethoprim (94.9%). No acquired AMR determinants for colistin, fosfomycin, or
317 tigecycline were detected. The virulence-associated yersiniabactin siderophore locus
318 (*ybt*) was detected in 10.5% of isolates (n=43/412). We did not identify any isolates
319 with hypervirulence-associated loci aerobactin, salmochelin, colibactin, *rmpADC* or
320 *rmpA2.*
321
322



Figure 1. Neighbour-joining tree of WGS-confirmed *K. pneumoniae*. ST is indicated by the colour of tree branch tips. 'Other STs' (pink tips) are those with ≤4 genomes identified: ST1486, ST340, ST268, ST45, ST14, ST1427, ST13, ST1731, ST20, ST253, ST280, ST405, ST54, ST831 and ST966. Heatmap indicates the presence (coloured block) or absence of acquired resistance genes corresponding to specific antibiotic classes (indicated by the block colour). Presence of the virulence-associated yersiniabactin locus is shown in the final column (grey).

Of the 411 *K. pneumoniae* isolates successfully sequenced and representing unique culture-positive neonates, 324 had associated clinical metadata available which included the date of NICU admission, and 263 of these had a specimen collection date recorded for the blood sample from which *K. pneumoniae* was cultured (**Table 2**). For neonates with both dates, the median day of onset of confirmed *K. pneumoniae* infection relative to admission was three days for both the baseline and post-implementation periods, and the proportion of sepsis classified as rapid-onset was similar in both periods (43.9% baseline vs 36.8% post-implementation, p=0.36). Amongst the 324 *K. pneumoniae* culture-positive neonates with clinical data, 279 had a recorded location of birth, with 205 inborn at UTH and 74 outborn (**Table 2**). The proportion of culture-positive neonates inborn at UTH was significantly lower in the post-implementation period (64.7% post-implementation vs 77.3% baseline, p=0.04).

345 **Table 2: Clinical characteristics of neonates with invasive *Klebsiella***
346 ***pneumoniae* disease during the baseline and post-implementation study**
347 **periods**
348

Characteristic	N[1]	Baseline N = 228[2]	Post-implementation N = 96[2]
Sex	279		
Male		94 (48%)	51 (60%)
Female		100 (52%)	34 (40%)
Unknown		34	11
Admission Date	324		
Present		228 (100%)	96 (100%)
Culture Date	263		
Present		187 (100%)	76 (100%)
Unknown		41	20
Clinical outcome	273		
Discharged		121 (64%)	45 (54%)
Died		68 (36%)	39 (46%)
Unknown		39	12
Birth location	279		
Inborn		150 (77%)	55 (65%)
Outborn		44 (23%)	30 (35%)
Unknown		34	11
Days to onset from admission	263		
0		16 (8.6%)	3 (3.9%)
1		33 (18%)	12 (16%)
2		33 (18%)	13 (17%)
3		35 (19%)	12 (16%)
4		20 (11%)	9 (12%)
5		15 (8.0%)	3 (3.9%)
6		11 (5.9%)	2 (2.6%)
7		12 (6.4%)	1 (1.3%)
8+ days		12 (6.4%)	21 (28%)
Unknown		41	20

[1] N = Total with non-missing data for this variable. [2] N (%) = Total with this value (values in brackets indicate percentage of total samples with non-missing data for this variable, N).

349
350 Of the 324 sequenced *K. pneumoniae* isolates with clinical metadata, the majority
351 (n=228, 70%) were isolated in the baseline period (based on date of specimen
352 collection where available or NICU admission date otherwise) (see **Table 2**, **Figure**
353 **2**). ST307 *K. pneumoniae* were present from the beginning of the study, with a
354 median 5 infections per week throughout the baseline period (mean 6.7 infections
355 per week for 31 weeks). The number of sequenced infections with ST307 declined to
356 zero after the IPC was implemented (mean 0.6, median 0 infections per week, weeks
357 32–73) (**Figure 2**). However, ST307 infections reappeared in weeks 54 and 56 (n=3)
358 and weeks 72 and 73 (n=6). A small number of sequenced infections with the

359 second most common sequence type, ST2004, occurred prior to the implementation
360 period (n=8, mean 1.3, median 1 infection per week over 6 weeks). However most
361 sequenced infections caused by ST2004 occurred during the post-implementation
362 period (n=39, mean of 2.4 and median of 2 infections per week over a 16-week
363 period) (**Figure 2**). ST101 was also associated with infections during both the
364 baseline (n=4) and post-implementation periods (n=5). In contrast, ST985 (n=5) and
365 ST147 (n=4) were identified amongst sequenced isolates from the baseline period
366 only, and ST983 (n=11) and ST15 (n=4) were identified post-implementation only
367 (**Figure 2**). ST983 infections were temporally clustered within a short time period
368 post-implementation (n=11 between weeks 33 and 38, mean 1.8 and median 1.5 per
369 week), and ST15 was detected post-implementation only, in weeks 71–73 (n=4, 1–2
370 per week for 3 weeks) (**Figure 2**). Eight other STs were detected during the study
371 period, mostly as single infections occurring sporadically during the study (n=10, see
372 **Figure 2**).
373
374



375
376 **Figure 2. Temporal distribution of WGS-confirmed *Klebsiella pneumoniae* invasive infections.**
377 Solid vertical lines represent the start of the post-implementation period, which continues to the study

end. **(A)** Timeline shows number of sequenced *K. pneumoniae* cases per week, belonging to each ST (one row per ST, also coloured by ST to match panel B). Each data point indicates one week, sized to indicate the number of isolates of the given ST per week. **(B)** Monthly counts of confirmed *K. pneumoniae* cases, stratified by ST. Total counts of cases per month are represented on each bar.

Transmission clusters

As the timeline of sequenced cases revealed temporal clustering by ST (**Figure 2A**), we undertook high-resolution genomic comparisons to investigate potential transmission patterns and explore changes following the IPC intervention (see **Methods**). Single-linkage clustering was done using a genetic distance threshold of ≤10 core genome SNVs and a temporal distance threshold of ≤28 days. Singleton STs were designated as non-clustered cases. Using these thresholds, clusters ranged in size from 2–202 neonates (median 6, IQR 4–11), and duration from within a single week to 33 weeks (median 3, IQR 2–5).

Overall, the proportion of cases belonging to clusters, or attributable to clusters, was significantly higher in the baseline period than the post-implementation period (n=221/226, 97.8% vs n=86/95, 90.5%, p=<0.01 and n=214/226, 94.7% vs n=78/95, 82.1% attributable, p=<0.001). To assess sensitivity of clustering to choice of thresholds, we additionally ran clustering with a range of pairwise distance thresholds, between 5–25 genome-wide SNVs and between 7–28 days, which yielded only minor differences in cluster number and size (**Supplementary Figure S2**). Varying SNV distance threshold had no impact on clustering for ST307, ST2004, ST983, ST147, ST15 and ST985. Only for ST101 did a SNV distance threshold of five have a minor impact on clustering compared to 10–25 SNVs. Varying the temporal threshold between 7–28 days had a small impact on the number of clusters and proportion of clustered sequences for ST307 ranging from (97.0% (225/232) in 8 clusters - 99.5% (231/232) in 5 clusters), ST101 (22% (2/9) in 1 cluster - 67% (6/9) in 2 clusters), ST2004 (94% (44/47) in 6 clusters - 100% (47/47) in 2 clusters), ST983 (100% (9/9) in 2 clusters - 100% (9/9) in 1 cluster) and ST147 (75% (3/4) in 1 cluster - 100% (4/4) in 1 cluster). In contrast, varying the temporal threshold had no impact on clustering for ST15 and ST985. Based on the range of estimates from these sensitivity analyses, between 292–306 (94.2–98.7%) of total cases were associated with a transmission cluster, and 272–293 out of 310 (87.7–94.5%) were attributable to nosocomial transmission.

Clustered sequences were not significantly associated with inborn vs outborn neonates (OR 1.23, 95% CI 0.32-3.89, p=0.7), or rapid-onset infection (OR 1.47, 95% CI 0.44-5.63, p=0.5). Of the 202 inborn neonates within the study hospital with a *K. pneumoniae* infection, 193 (95.5%) were within a cluster, and 9 (4.5%) were not. Proportions were similar in outborn neonates in which 70/74 (94.6%) of infections were clustered. Of the 110 neonates with rapid-onset infection, 106 (96.4%) isolates were clustered, and similarly, 144/152 (94.7%) isolates from neonates with delayed-onset infection were clustered. For neonates with data in both (n=236), inclusion of an interaction term between birth location and onset category did not yield a statistically significant effect (p=0.3), despite changes in the estimated odds ratios.

During the baseline period, all identified clusters included infections in both inborn and outborn neonates (**Figure 3A**). ST147 cluster 1 comprised exclusively delayed-

428 onset infections (n=4; 3 inborn, 1 outborn), and ST985 cluster 1 was predominantly
429 delayed-onset (4/5; 2 inborn, 2 outborn), with one rapid-onset case in an outborn
430 neonate. Neither ST was observed in post-implementation clusters. Metadata for
431 ST2004 cluster 1 was limited, 2 of 8 neonates were outborn with delayed-onset
432 infections; one additional case involved a neonate with delayed-onset infection and
433 unknown birth location, and another was an inborn neonate with an unknown onset
434 category infection (**Figure 3A**). In contrast, post implementation ST2004 cluster 2
435 infections included both rapid-onset (8/39) as well as delayed-onset (22/39)
436 infections, occurring predominantly in inborn (21/39) compared to outborn (16/39)
437 neonates (**Figure 3B**).
438



439
440 **Figure 3. Breakdown of birth location and onset category for infections in each cluster, divided**
441 **into those detected (A) at baseline and (B) post-implementation.** Individual plots are labelled with
442 ST and cluster number. Clusters were assigned to baseline or post-implementation based on the
443 timing of the first case in the cluster. Onset category is defined as 'rapid-onset' (day 0-2 of admission
444 to NICU) or 'delayed-onset' (day 3+ of admission to NICU). ST101 cluster 1 is not shown due to lack
445 of any data on birth location or onset category for all cases.
446

ST307 cluster 1 was the largest, comprising 202 infections, predominantly among inborn neonates (68.8%, 139/202). Among those inborn neonates, rapid- and delayed-onset infections occurred in equal proportions (42.4%, 59/139 for both) similarly to proportions in outborn neonates (35.3% rapid-onset, 52.9% delayed-onset). ST307 cluster 2 involved equal numbers of inborn and outborn (n=3 each) neonates, with most infections being delayed-onset (5/7; 3 inborn, 1 outborn, 1 unknown). ST307 cluster 3, first detected at baseline (n=1), persisted into the post-implementation period and included both inborn (n=5) and outborn (n=4) neonates, with 50% each of rapid-onset and late-onset infections (**Figure 3A**).

Two novel ST307 clusters emerged post-implementation (**Figure 3B**). Cluster 4 caused exclusively delayed onset infections (n=3), affecting one inborn and two outborn neonates—distinct from the mixed onset pattern seen in earlier ST307 clusters. In contrast, cluster 5 predominantly caused rapid-onset infections (4/6), all in inborn neonates. Additional post-implementation clusters included ST101 cluster 2, which caused delayed-onset infections in two inborn neonates. Two new clustered STs, ST15 cluster 1 which included rapid-onset infections in inborn neonates (n=2) and delayed-onset infections in outborn neonates (n=2). The second, ST983 cluster 1, was predominantly detected in inborn neonates (10/11), causing both rapid- (n=6) and delayed-onset (n=2) infections (**Figure 3B**).

Persistence vs novel introductions

Three STs (ST307, ST2004 and ST101) were identified both at baseline and post-implementation. To explore whether post-implementation infections may have arisen from contamination persisting during the intervention or represented new strain introduction into the unit, we conducted additional phylogenomic analyses (see **Methods**).

The ST307 phylogeny revealed a dominant sublineage accounting for n=248/285 ST307 genomes (cluster 1, green in **Figure 4**). Of these, 202 had known dates of admission and 180 had a known specimen collection date; these all belonged to cluster 1 and were detected throughout the baseline period (n=31 weeks, median 5 cases per week) and during the first three weeks post-implementation, but not after month eight. Four other ST307 sublineages were evident in the tree, mapping to clusters 2–5 (**Figure 4**). Cluster 3 was first detected two weeks prior to the IPC intervention (n=1) and persisted into the post-implementation period (n=11, median 1 per week for 9 weeks) but was not detected after this. One other cluster (cluster 2) was detected prior to intervention (n=7, median 1 per week for four weeks); and two clusters were detected during the post-implementation period (cluster 4; n=3, median 1.5 per week for three weeks in month 13; and cluster 5; n=6, median three per week for two weeks in month 17) (**Figure 4**). No ST307 cases sequenced from the post-implementation period (cluster 4 and 5) belonged to the same phylogenetic lineage as baseline isolates (cluster 1, 2 and 3), and the minimum pairwise genetic distance between cluster 4 or 5 and any other isolates was 71 SNVs. Therefore, the ST307 infections identified post-implementation appear to be unrelated to the ST307 sublineage responsible for the earlier infection clusters.



Figure 4. Core SNV phylogenies of *Klebsiella pneumoniae* aligned to acquired AMR gene data and infection timelines. ST307 isolates (top), **ST101** isolates (middle) and **ST2004** isolates (bottom). A midpoint-rooted maximum-likelihood phylogenetic tree was inferred separately for each ST, based on an alignment of SNVs identified against a closed reference genome of that ST. Tips are coloured to indicate the cluster number, inferred via single-linkage clustering using thresholds of ≤10 SNVs and ≤28 days. X-axis below each tree indicates phylogenetic distance expressed as number of SNVs. Heatmaps show the presence of key acquired resistance genes and hypervirulence genes (if present) aligned to tree tips. Timeline plot indicates the date of isolation (study week) for each isolate, aligned to tree tips and coloured by cluster number. The timing of the start of the IPC implementation is indicated by a solid vertical line.

To assess the impact of using admission date as a proxy for date of *K. pneumoniae* isolation (in n=61 cases with an admission date, but lacking a recorded culture date),

509 an additional clustering sensitivity analysis was conducted for ST307
510 (**Supplementary Figure S3**). Clustering based solely on isolates with a known
511 culture date (**Supplementary Figure S3B**) identified the same isolates present in
512 clusters, but separated the very large cluster into two, separated by an intervening
513 period of 32 days between culture dates in month 5 and month 6.
514
515 All except one ST307 isolate carried $bla_{CTX\text{-}M\text{-}15}$, and the different subgroups of ST307
516 presented overall similar AMR profiles, with the exception of cluster 4 in which
517 n=9/12 isolates carried *aadA2* instead of *aac(3')-IIa* (suggesting loss of gentamicin
518 resistance) and *dfrA12* instead of *dfrA14* (retention of trimethoprim resistance).
519 Cluster 3 and 4 additionally carried *mphA* and *mrx* genes (suggesting reduction of
520 azithromycin susceptibility), and *sul1* in addition to *sul2* (retention of trimethoprim-
521 sulfamethoxazole resistance). The acquired siderophore, yersiniabactin, was present
522 in clusters 2 and 4 only (**Figure 4**).
523
524 The ST101 core SNV phylogeny revealed a sub-lineage of seven genetically related
525 isolates, and two genetically distant isolates (**Figure 4**). The genetically-linked
526 isolates were temporally divided into two clusters, one during the baseline period
527 (n=2 cases, isolated in the same week) and a second during the post-implementation
528 period (n=4 cases over 6 weeks) (**Figure 4**). The seventh isolate was just seven
529 SNVs different and detected four weeks after the last cluster-2 case. Clusters 1 and
530 2 were not genetically distinct, separated by 0–7 pairwise SNVs and sharing the
531 same AMR profile, consistent with persistence of a single clone from the baseline to
532 the post-implementation period (**Figure 4**).
533
534 The ST2004 phylogeny revealed a dominant sub-lineage, split into two temporally
535 separated clusters of genetically near-identical isolates (**Figure 4**). Cluster 1 was
536 detected during the baseline period (n=8 cases, median 1 per week for 6 weeks),
537 and cluster 2 in the post-implementation period (n=39 cases, median 2 cases per
538 week for 16 weeks) (**Figure 4**). Pairwise genetic distances between these two
539 clusters were 0-5 SNVs, with identical resistance profiles, again consistent with long-
540 term persistence of a single clone.
541
542 The remaining four STs with ≥4 infection isolates (ST15, ST147, ST983 and ST985),
543 detected in either the baseline period or the post-implementation period, could not be
544 phylogenetically represented due to low intra-sequence diversity. For each of these
545 STs, the maximum number of SNVs between all genomes was three (Full SNV data
546 is available at https://github.com/klebgenomics/SPINZ). AMR profiles and infections
547 by study week for these STs are shown in **Supplementary Figure S4**.
548
549 *Serotypes and AMR post intervention*
550
551 The prevalence of predicted K-types differed significantly between the baseline and
552 post-implementation periods ($p<0.001$ using Chi-square test) (**Figure 5A**), driven by
553 changes in the prevalence of associated STs. Most notably, infections in the
554 baseline period were dominated by a large cluster of ST307 with disruptions in the
555 KL102 locus, which were assigned by Kaptive as capsule null (87.1% of infections),
556 whereas the post-implementation period was dominated by KL23 ST2004 (43.8%),
557 KL102 ST307 (24.7%) and KL127 ST983 (12.4%). The KL102-disrupted ST307
558 isolates belonging to ST307 cluster 1, shared a deletion of 661 base pairs truncating

559 the *wbaP* and *wzy* genes within the capsule locus (**Supplementary Figure S5**) that
560 are likely to result in a lack of capsule synthesised via this locus. The distribution of
561 predicted O loci also differed in the post-implementation periods compared with
562 baseline (**Figure 5B**), most notably with reduced prevalence of OL2α.2 loci (96.4%
563 vs 82.0%) and introduction of O13 (0% vs 12.4%) via the ST983 cluster.
564



565
566 **Figure 5. Prevalence of K-loci (A) and O-loci (B), and mean number of acquired AMR genes (C)**
567 **detected amongst *K. pneumoniae* isolated in the baseline and post-implementation study**
568 **periods.**
569

570 AMR gene profiles were very similar across STs and clusters (**Figure 1**), and
571 consequently there were few changes post-implementation (**Figure 5C**). There was
572 an increase in presence of azithromycin resistance-associated genes post-
573 implementation (from 3.1%, n=7/228 to 22.9%, n=22/96), driven by the presence of
574 *mphA* in the post-implementation ST307 clusters 3 and 4. In ST307 cluster 4
575 genomes, the *mphA* gene was carried on a 6 kilobase pairs (kbp) contig flanked by
576 repeat sequences (transposases). The location could therefore not be fully resolved
577 from short read sequence data, however inspection of the assembly graph suggests
578 it was likely located in a plasmid with similarity to a *mphA*-carrying reference plasmid
579 with GenBank accession CP021752.1 (identified as a close reference using MOB-
580 suite), as this plasmid was present in the assembly graphs (96.9% coverage at mean
581 98.6% identity) and connected the *mphA* contig (**Supplementary Figure S6**). The
582 location of *mphA* was even harder to resolve in cluster 3 genomes, where it was
583 located on a 3.2 kbp contig. However, the reference plasmid CP021752.1 had only
584 74% coverage in these genomes, suggesting this cluster may harbour a distinct
585 *mphA* plasmid.
586

587 **Discussion**

588
589 Analysis of high quality WGS data from 411 *K. pneumoniae* blood isolates from
590 neonates showed that most infections (95.6%) belonged to temporal clusters of
591 near-identical isolates, consistent with nosocomial transmission. The fraction of
592 clustered isolates was the same amongst neonates inborn at UTH and those born
593 elsewhere before admission to the NICU, with clustering not shown to be associated
594 with birth location, rapid-onset of infection (day 0-2 of NICU admission), or their
595 interaction. This finding is consistent with nosocomial transmission in the NICU
596 specifically (as opposed to e.g. the labour ward).
597
598 The primary SPINZ analysis reported previously that sepsis incidence declined
599 following implementation of the IPC bundle (22). Here, the new *K. pneumoniae* WGS
600 data support that the IPC bundle successfully disrupted a large, long-running
601 outbreak of *K. pneumoniae* ST307 that persisted throughout the baseline
602 observation period (median 5 new infections per week) but disappeared three weeks
603 after the implementation began. The data also showed the fraction of *K. pneumoniae*
604 infections involved in clusters to be smaller post-implementation (97.8% vs 90.5%,
605 p=<0.01), consistent with an effect of the implementation. However, the overall
606 cluster rate remained high compared with similar estimates from other African NICUs
607 (38) and indicated ongoing challenges with maintaining effective IPC.
608
609 Notably, a substantial proportion of infections (26.8%), and of clustered infections
610 (34.5%), were rapid-onset, identified within two days of admission to the NICU. This
611 differs from the usual definition of healthcare-associated infection (HCAI) which
612 designates infections occurring after a hospital stay of two days or more (39).
613 However, here we observed multiple cases of neonates with *K. pneumoniae* isolated
614 from blood stream infections on day 0 or 1 of NICU admission, with isolates
615 genetically identical to those from other patients on the same ward within days.
616 This includes outborn infants, providing compelling evidence of transmission within
617 the NICU as opposed to acquisition from a common source outside the unit prior to
618 admission. Recent outbreak investigations in other African NICUs have identified

619 diverse sources of infection including contaminated environments (e.g. sinks, bed
620 railings), water sources and colonised healthcare workers as well as contaminated
621 reagents including IV bags (40-42). It is plausible that outbreaks mediated by
622 contaminated reagents, which are directly inoculated into newborns via injection or
623 feeding tubes, could result in rapid-onset infections. In contrast, transmission
624 mediated by environmental contamination of colonised healthcare workers may be
625 more likely to begin with gut colonisation of neonates, followed by overgrowth in the
626 gut before progressing to systemic infection and sepsis, better fitting the standard
627 expectations of HCAI onset after ≥2 days on the ward. Consistent with this, the
628 distribution of rapid-onset infections was skewed, with six putative transmission
629 clusters including very few (0 or 1) rapid-onset infections, while four clusters—most
630 notably the large, persistent ST307 baseline cluster 1—were dominated by rapid-
631 onset infections, often including babies born outside the hospital. During the baseline
632 period, most clusters were composed of delayed-onset infections (≥2 days post
633 admission). However, following implementation of the IPC bundle, 3 out of 6 clusters
634 included at least half, or a majority, rapid-onset infections. This shift may indicate the
635 IPC measures effectively eliminated outbreak sources linked to environmental
636 contamination or poor hand hygiene, while more direct sources, such as
637 contaminated reagents, may have persisted. This explanation would be consistent
638 with the nature of the IPC bundle, however no environmental or reagent screening
639 was undertaken during the study period to enable a direct assessment of outbreak
640 sources post-implementation, and whether they differed in nature to the baseline
641 period sources. This raises an important consideration for future studies assessing
642 the effectiveness of IPC interventions.
643
644 Infections with ST101 and ST2004 were associated with clusters in both the baseline
645 and post-implementation periods, with genetically indistinguishable strains isolated in
646 both periods. For ST101, we observed two infections in the same week (week 6
647 during baseline), then four infections during weeks 39-44 in the post-implementation
648 period (0-7 SNVs from the first two cases, see **Figure 4B and Supplementary**
649 **Figure S7**), and a single infection 4 weeks later (7 SNVs). The timing of onset
650 information was unknown for the two baseline infections, however the second cluster
651 of infections were all delayed onset (day 5-15 following NICU admission) and the
652 single infection in week 48 was also delayed onset, following 41 days in the NICU
653 (i.e. the infant was already present on the ward during the 4-case cluster, so could
654 have become colonised around the same time as the others). For ST2004 we
655 observed a cluster of eight infections in weeks 4-9 and a second cluster of 39
656 infections between weeks 45-60, with 0-5 SNVs between the two clusters. For the
657 first cluster, timing of onset was known for three babies, all of whom had delayed-
658 onset (3-7 days following admission to NICU); the later cluster included eight rapid-
659 onset infections (in two inborn babies and six outborn) and 22 that were known to be
660 delayed onset (3-39 days). We hypothesise these patterns could be explained by
661 some form of environmental contamination present during the baseline period, which
662 persisted through the IPC intervention, and occasionally transmitted to additional
663 sources that resulted in temporally clustered infections.
664
665 The high numbers of cases of neonatal sepsis with *K. pneumoniae* overall and
666 diversity of STs (24 among 411 isolates) over a 19-month period is similar to findings
667 in other settings (43). The high level of diversity can be linked to the various
668 reservoirs that could be introducing pathogens such as *K. pneumoniae* into the NICU

environment, including healthcare workers, parents, medical equipment, and other environmental fomites (44). Some of the *K. pneumoniae* lineages associated here with nosocomial transmission (ST307, ST101, ST147, ST15) are considered high-risk clones that have been associated with HCAI outbreaks in other settings including neonatal units across continents as well as within adult ICUs in high-income countries (45, 46). In particular the most common ST, associated with five clusters and a majority of infections, was ST307. Since its emergence in the mid-1990s (47), ST307 has rapidly spread across every continent except Antarctica, causing nosocomial outbreaks worldwide (48-50). One such outbreak in a Korean NICU was reportedly controlled through enhanced IPC measures, including frequent disinfection of medical devices, active surveillance cultures, hand hygiene re-education, and segregation of infected and newly admitted individuals (51). Although *Klebsiella pneumoniae* ST307 has been reported in Africa, including Zambia, it appears less frequently than in Europe and the USA. To our knowledge this is the first study to perform genomic characterization using WGS, including sequence typing and AMR gene profiling, to explore the prevalence and distribution of STs.

Notably, the ST307 strain causing the very large cluster (>200 infections during baseline observation) had a disrupted KL102 locus (**Supplementary Figure S5**), which was predicted as capsule-null by the Kaptive genotyping tool (20).The two truncated genes, *wbaP* and *wzy*, are thought to encode proteins essential for capsule formation, responsible for the initiation of the synthesis of the capsular repeat units and their polymerisation, respectively (52). Capsule-null *K. pneumoniae* are rarely observed in blood isolates, consistent with the role of the capsule in evading serum complement and phagocytosis (53, 54). However capsule inactivation has been reported in clinical isolates from other body sites, and may enhance epithelial cell invasion, biofilm formation and persistence particularly in urinary tract infections (55). ST307 genomes harbour a second putative polysaccharide locus, Cp2 (56), that was intact in all cluster 1 ST307 genomes, and may encode an alternative capsule. We were unable to retrieve isolates to experimentally confirm whether cluster 1 ST307 isolates were encapsulated. Previous reports of a KL102-disrupted ST307 with intact Cp2 loci display reduced complement resistance when tested against sera from healthy adult volunteers (4-log reduction after two hours). However, this reduced level of resistance may still be sufficient to infect neonates, whose complement systems are underdeveloped (57). Given the susceptibility of unencapsulated bacteria to host immune defences, it is unlikely these isolates lacked a capsule yet maintained sustained transmission at the observed scale over a sustained period of time. This observation, alongside the dynamic shifts in K-type prevalence, underscores the importance of considering both O- and K-antigen variability in the design of a maternal vaccine. The detection of a second capsule locus in ST307—and potentially in other sequence types—raises concerns about selective pressure driving capsule switching or alternative polysaccharide expression, potentially undermining vaccine efficacy. Genomic surveillance plays a critical role not only in identifying transmission clusters but also in characterizing the circulating *K. pneumoniae* population—an essential step in informing vaccine target selection and coverage.

The next most prevalent ST, ST2004 is much less well described. It was first defined from a 2015 Chinese isolate (58) and has publicly available genome data from China, Japan, Australia, Europe and USA, but no cases reported previously from

719 Africa. There is insufficient data to determine the origin of this ST or the likelihood of
720 importation from one of the countries listed above. However, the nearest neighbours
721 in Pathogenwatch, based on LINcodes, were identified in Switzerland and the
722 Netherlands, showing 0.32-0.64% allelic diversity. Most public ST2004 genomes
723 include $bla_{CTX\text{-}M\text{-}15}$, as we observed in this study, suggesting this may be an emerging
724 ESBL clone.
725
726 Profiling of AMR genes predicted most *K. pneumoniae* isolated in this study were
727 multi-drug resistant, with 99% carrying ESBL genes and a number of STs belonging
728 to known MDR lineages (59-62). The majority of isolates carried acquired genes
729 associated with resistance to aminoglycosides, ß-lactams (including ESBLs),
730 fluoroquinolones and trimethoprim-sulfamethoxazole. No substantial change in
731 genotypic AMR profiles was seen following the implementation of the IPC bundle
732 (**Figure 5C**), which is as expected given there was no change in antimicrobial use.
733 However, we did observe the introduction of *mphA* in ST307 clusters 2 and 4. While
734 azithromycin is not typically used to treat neonatal sepsis, its use prophylactically to
735 reduce maternal and neonatal postpartum infections has been studied. A recent
736 review found modest benefits for maternal outcomes but no effect on neonatal
737 adverse outcomes (63). Intrapartum antibiotics may also alter the neonatal
738 microbiome and increase AMR gene abundance, particularly in *K. pneumoniae* (64-
739 67). Several studies have reported elevated prescribing rates in Zambian hospitals,
740 surpassing WHO prescribing indicators (68, 69), potentially sustaining the presence
741 of MDR pathogens within the hospital environment.
742
743 A small number of isolates carried a $bla_{NDM\text{-}5}$ carbapenemase gene, belonging to
744 ST340 (n=2) and ST5856 (n=9). These isolates could not be linked to clinical
745 metadata and so were not included in cluster analysis, however they clustered
746 closely genetically (0-8 SNVs between ST340 isolates, 0-14 SNVs between ST5856
747 isolates based on Pathogenwatch clustering), indicative of some form of local
748 transmission either within the unit or the community. Despite numbers being low, this
749 finding is of concern given the role of carbapenems as a last line treatment option for
750 *K. pneumoniae*. More recent data from the same hospital indicates an increase in
751 carbapenem resistance amongst *K. pneumoniae* clinical isolates from adult patients
752 (imipenem resistance rose from 3% in 2015, when the SPINZ study commenced, to
753 19% in 2020), and high rates of carbapenem resistance amongst *K. pneumoniae*
754 isolated from the NICU environment (88% resistant to meropenem in 2023),
755 suggesting that carbapenem resistance has likely escalated in this setting since the
756 conclusion of the study (70).
757
758 There are limitations to this work, primarily related to the fact that the WGS analysis
759 was carried out retrospectively, and was not part of the original study design. This
760 resulted in incomplete clinical data and limited linkage between laboratory and
761 clinical datasets, ultimately constraining the scope and depth of the analysis. The
762 presence of missing data also introduces potential biases that cannot be fully
763 accounted for. Beyond these constraints, had the study been prospectively designed
764 with the current analysis in mind, additional measures could have significantly
765 enhanced the completeness and interpretability of the findings. For instance, our
766 results suggest the elimination of some sources and persistence of others, indicated
767 by the relatedness of strains before and after the IPC implementation. Incorporating
768 environmental sampling during the study period could have provided direct

information on the reservoirs and transmission pathways of *K. pneumoniae* on the unit, offering more specific actionable insights regarding IPC failures and guiding future intervention efforts. An additional limitation of this analysis is the exclusive use of short-read Illumina sequencing, which lacks the resolution to accurately assemble plasmids compared to Nanopore long-read data. Incorporating long-read sequencing would enhance the detection of plasmid structures and associated AMR gene content.

In conclusion, this WGS analysis of isolates collected from the SPINZ study (22) highlights the value of genomic surveillance in informing and monitoring IPC interventions in neonatal units, even when applied retrospectively. Delivery of IPC best practices in LMIC healthcare facilities may be compromised by unpredictable water supply, high patient-to-nurse ratios, facility overcrowding, personal protective equipment and hand hygiene supply shortages, reuse of single-use items, and high burden of AMR colonization and infection, among other factors (71, 72). Evidence shows that despite most neonatal units having IPC and cleaning guidelines, adequate infrastructure and consumables to support optimal IPC are lacking (73). Additionally, bacterial pathogens have adapted characteristics to enable survival on surfaces and medical equipment, such as the ability to form biofilms (74), increasing resistance to cleaning and disinfectants (75). The WHO guidelines for IPC issued in 2016 outline eight core components for the implementation of effective IPC, however the feasibility of application depends greatly on settings, and guidelines must be adapted based on feasibility (18). Notably, identifying and containing outbreaks, particularly in low-resource settings, presents distinct challenges due to often limited infection control training, inadequate infrastructure, and constrained healthcare resources (76). In the NICU studied here, persistent overcrowding and a patient-to-nurse ratio of 20:1 further hinder efforts to prevent transmission among neonates.

Acknowledgements

We thank the participants and their families in the SPINZ study, and the clinical and laboratory staff involved in collection and processing of relevant data and isolates. We also thank Andrew Page, David Baker, Leonardo de Oliveira Martins and the Core Sequencing and Bioinformatics teams at the Quadram Institute (QIB), Norwich, United Kingdom for their assistance with Illumina sequencing. This work was supported by Monash eResearch capabilities, including M3. We thank the Institut Pasteur teams for the curation and maintenance of BIGSdb-Pasteur databases at http://bigsdb.pasteur.fr/.

References:

1. Perin J, Mulick A, Yeung D, Villavicencio F, Lopez G, Strong KL, et al. Global, regional, and national causes of under-5 mortality in 2000-19: an updated systematic analysis with implications for the Sustainable Development Goals. The Lancet Child & Adolescent Health. 2022;6(2):106-15.
2. Lawn JE, Cousens S, Zupan J. 4 million neonatal deaths: When? Where? Why? The Lancet. 2005;365(9462):891-900.
3. Li J, Xiang L, Chen X, Li S, Sun Q, Cheng X, et al. Global, regional, and national burden of neonatal sepsis and other neonatal infections, 1990–2019: findings from the Global Burden of Disease Study 2019. European Journal of Pediatrics. 2023;182(5):2335-43.
4. Sands K, Carvalho MJ, Portal E, Thomson K, Dyer C, Akpulu C, et al. Characterization of antimicrobial-resistant Gram-negative bacteria that cause neonatal sepsis in seven low- and middle-income countries. Nature Microbiology. 2021;6(4):512-23.
5. Shukla V, Mwenechanya M, Carlo WA. Dealing with neonatal emergencies in low-resource settings. Seminars in Fetal and Neonatal Medicine. 2019;24(6).
6. Okomo U, Akpalu ENK, Le Doare K, Roca A, Cousens S, Jarde A, et al. Aetiology of invasive bacterial infection and antimicrobial resistance in neonates in sub-Saharan Africa: a systematic review and meta-analysis in line with the STROBE-NI reporting guidelines. The Lancet Infectious Diseases. 2019;19(11):1219-34.
7. Russell NJ, Stöhr W, Plakkal N, Cook A, Berkley JA, Adhisivam B, et al. Patterns of antibiotic use, pathogens, and prediction of mortality in hospitalized neonates and young infants with sepsis: A global neonatal sepsis observational cohort study (NeoOBS). PLOS Medicine. 2023;20(6):e1004179.
8. Naghavi M, Vollset SE, Ikuta KS, Swetschinski LR, Gray AP, Wool EE, et al. Global burden of bacterial antimicrobial resistance 1990-2021: a systematic analysis with forecasts to 2050. The Lancet. 2024;404(10459):1199-226.
9. Harrison ML, Dickson BF, Sharland M, Williams PC. Beyond early-and late-onset neonatal sepsis definitions: what are the current causes of neonatal sepsis globally? A systematic review and meta-analysis of the evidence. The Pediatric Infectious Disease Journal. 2024;43(12):1182-90.
10. World Health Organization. WHO Bacterial Priority Pathogens List, 2024: bacterial pathogens of public health importance to guide research, development and strategies to prevent and control antimicrobial resistance.; 2024.
11. Santos RP, Tristram D. A practical guide to the diagnosis, treatment, and prevention of neonatal infections. Pediatric Clinics. 2015;62(2):491-508.
12. Dramowski A, Bolton L, Fitzgerald F, Bekker A. Neonatal Sepsis in Low-and Middle-income Countries: Where Are We Now? The Pediatric infectious disease journal. 2025;44(6):e207-e10.
13. Dangor Z, Benson N, Berkley JA, Bielicki J, Bijsma MW, Broad J, et al. Vaccine value profile for *Klebsiella pneumoniae*. Vaccine. 2024;42(19, Supplement 1):S125-S41.
14. Kumar CK, Sands K, Walsh TR, O'Brien S, Sharland M, Lewnard JA, et al. Global, regional, and national estimates of the impact of a maternal *Klebsiella pneumoniae* vaccine: A Bayesian modeling analysis. PLOS Medicine. 2023;20(5):e1004239.
15. Gill CJ, Mantaring JBV, Macleod WB, Mendoza M, Mendoza S, Huskins WC, et al. Impact of Enhanced Infection Control at 2 Neonatal Intensive Care Units in The Philippines. Clinical Infectious Diseases. 2009;48(1):13-21.

16. Igwe U, Okolie OJ, Ismail SU, Adukwu E. Effectiveness of infection prevention and control interventions in health care facilities in Africa: A systematic review. American Journal of Infection Control. 2024;52(10):1135-43.
17. Qadir M, Resham S, Naz F, Ahmad K, Ahmed S, Ali R, et al. Effectiveness of simple strategies in reducing multidrug resistant bloodstream infections in the NICU of a tertiary care hospital in Karachi, Pakistan. International Journal of Infectious Diseases. 2012;16:e383.
18. World Health Organization. Health care without avoidable infections: the critical role of infection prevention and control. https://www.who.int/publications/i/item/WHO-HIS-SDS-2016.10. 2016.
19. Young-Sharma T, Lane CR, James R, Wilmot M, Autar S, Hui K, et al. Successful management of a multi-species outbreak of carbapenem-resistant organisms in Fiji: a prospective genomics-enhanced investigation and response. The Lancet Regional Health – Western Pacific. 2024;53.
20. Stanton TD, Hetland MAK, Löhr IH, Holt KE, Wyres KL. Fast and accurate in silico antigen typing with Kaptive 3. Microbial Genomics. 2025;11(6).
21. Stanton TD, Keegan SP, Abdulahi JA, Amulele AV, Bates M, Heinz E, et al. Distribution of capsule and O types in *Klebsiella pneumoniae* causing neonatal sepsis in Africa and South Asia: meta-analysis of genome-predicted serotype prevalence and potential vaccine coverage. medRxiv. 2025: 10.1101/2025.06.28.25330253.
22. Mwananyanda L, Pierre C, Mwansa J, Cowden C, Localio AR, Kapasa ML, et al. Preventing Bloodstream Infections and Death in Zambian Neonates: Impact of a Low-cost Infection Control Bundle. Clinical Infectious Diseases. 2019;69(8):1360-7.
23. Egbe FN, Cowden C, Mwananyanda L, Pierre C, Mwansa J, Lukwesa Musyani C, et al. Etiology of Bacterial Sepsis and Isolate Resistance Patterns in Hospitalized Neonates in Zambia. The Pediatric Infectious Disease Journal. 2023;42(10):921-6.
24. Foster-Nyarko E, Alikhan N-F, Ravi A, Thilliez G, Thomson NM, Baker D, et al. Genomic diversity of *Escherichia coli* isolates from non-human primates in the Gambia. Microbial Genomics. 2020;6(9).
25. Argimón S, David S, Underwood A, Abrudan M, Wheeler NE, Kekre M, et al. Rapid Genomic Characterization and Global Surveillance of Klebsiella Using Pathogenwatch. Clinical Infectious Diseases. 2021;73(Supplement_4):S325-S35.
26. Lam MMC, Wick RR, Watts SC, Cerdeira LT, Wyres KL, Holt KE. A genomic surveillance framework and genotyping tool for *Klebsiella pneumoniae* and its related species complex. Nature Communications. 2021;12(1):4188.
27. Underwood A. BactInspector 2019 [Available from: https://gitlab.com/antunderwood/bactinspector].
28. Seemann T. Snippy 2020 [Available from: https://github.com/tseemann/snippy].
29. Taouk ML, Featherstone LA, Taiaroa G, Seemann T, Ingle DJ, Stinear TP, et al. Exploring SNP filtering strategies: the influence of strict vs soft core. Microbial Genomics. 2025;11(1).
30. Croucher NJ, Page AJ, Connor TR, Delaney AJ, Keane JA, Bentley SD, et al. Rapid phylogenetic analysis of large samples of recombinant bacterial whole genome sequences using Gubbins. Nucleic Acids Research. 2015;43(3):e15-e.
31. Kozlov AM, Darriba D, Flouri T, Morel B, Stamatakis A. RAxML-NG: a fast, scalable and user-friendly tool for maximum likelihood phylogenetic inference. Bioinformatics. 2019;35(21):4453-5.

32. Yu G. Data Integration, Manipulation and Visualization of Phylogenetic Trees (1st ed.): Chapman and Hall/CRC; 2022. 276 p.
33. Odih EE. transmission_estimator. 2024. [Available form: https://github.com/klebgenomics/transmission_estimator.git].
34. Robertson J, Nash JHE. MOB-suite: software tools for clustering, reconstruction and typing of plasmids from draft assemblies. Microbial Genomics. 2018;4(8).
35. Seemann T. Abricate: GitHub; 2023 [Available from: https://github.com/tseemann/abricate].
36. Jia B, Raphenya AR, Alcock B, Waglechner N, Guo P, Tsang KK, et al. CARD 2017: expansion and model-centric curation of the comprehensive antibiotic resistance database. Nucleic Acids Research. 2016;45(D1):D566-D73.
37. Wick RR, Schultz MB, Zobel J, Holt KE. Bandage: interactive visualization of de novo genome assemblies. Bioinformatics. 2015;31(20):3350-2.
38. Odih EE, Abdulahi JA, Amulele AV, Bates M, Heinz E, Hu W, et al. Contribution of nosocomial transmission to *Klebsiella pneumoniae* neonatal sepsis in Africa and South Asia: a meta-analysis of infection clusters inferred from pathogen genomics and temporal data. medRxiv. 2025.
39. Bunduki GK, Masoamphambe E, Fox T, Musaya J, Musicha P, Feasey N. Prevalence, risk factors, and antimicrobial resistance of endemic healthcare-associated infections in Africa: a systematic review and meta-analysis. BMC Infectious Diseases. 2024;24(1):158.
40. Muyldermans A, Crombé F, Bosmans P, Cools F, Piérard D, Wybo I. *Serratia marcescens* outbreak in a neonatal intensive care unit and the potential of whole-genome sequencing. Journal of Hospital Infection. 2021;111:148-54.
41. Bicking Kinsey C, Koirala S, Solomon B, Rosenberg J, Robinson BF, Neri A, et al. *Pseudomonas aeruginosa* Outbreak in a Neonatal Intensive Care Unit Attributed to Hospital Tap Water. Infection Control & Hospital Epidemiology. 2017;38(7):801-8.
42. Strysko J, Hu W, Mochankana K, John-Thubuka J, Zankere T, Gopolang B, et al. Using Genomic and Traditional Epidemiologic Approaches to Define Complex Transmission Pathways of *Klebsiella pneumoniae* Infection in a Neonatal Unit in Botswana, 2022–2023. medRxiv. 2025:10.1101/2025.11.06.25339637.
43. Fau MR, Ismail H, Lowe M, Strasheim W, Mogokotleng R, Perovic O, et al. Outbreak of NDM-1- and OXA-181-Producing *Klebsiella pneumoniae* Bloodstream Infections in a Neonatal Unit, South Africa. Emerging Infectious Diseases. 2023 ;29(8):1531-1539.
44. Elkady MA, Bakr WMK, Ghazal H, Omran EA. Role of environmental surfaces and hands of healthcare workers in perpetuating multi-drug-resistant pathogens in a neonatal intensive care unit. European Journal of Pediatrics. 2022;181(2):619-28.
45. Navon-Venezia S, Kondratyeva K, Carattoli A. *Klebsiella pneumoniae*: a major worldwide source and shuttle for antibiotic resistance. FEMS Microbiology Reviews. 2017;41(3):252-75.
46. Wyres KL, Lam MMC, Holt KE. Population genomics of *Klebsiella pneumoniae*. Nature Reviews Microbiology. 2020;18(6):344-59.
47. Wyres KL, Hawkey J, Hetland MAK, Fostervold A, Wick RR, Judd LM, et al. Emergence and rapid global dissemination of CTX-M-15-associated *Klebsiella pneumoniae* strain ST307. Journal of Antimicrobial Chemotherapy. 2019;74(3):577-81.

48. Strydom KA, Chen L, Kock MM, Stoltz AC, Peirano G, Nobrega DB, et al. *Klebsiella pneumoniae* ST307 with OXA-181: threat of a high-risk clone and promiscuous plasmid in a resource-constrained healthcare setting. Journal of Antimicrobial Chemotherapy. 2020;75(4):896-902.
49. Heiden SE, Hübner N-O, Bohnert JA, Heidecke C-D, Kramer A, Balau V, et al. A *Klebsiella pneumoniae* ST307 outbreak clone from Germany demonstrates features of extensive drug resistance, hypermucoviscosity, and enhanced iron acquisition. Genome Medicine. 2020;12(1):113.
50. Haller S, Kramer R, Becker K, Bohnert JA, Eckmanns T, Hans JB, et al. Extensively drug-resistant *Klebsiella pneumoniae* ST307 outbreak, north-eastern Germany, June to October 2019. Eurosurveillance. 2019;24(50):1900734.
51. Baek E-H, Kim S-E, Kim S, Lee S, Cho O-H, In Hong S, et al. Successful control of an extended-spectrum beta-lactamase-producing Klebsiella pneumoniae ST307 outbreak in a neonatal intensive care unit. BMC Infectious Diseases. 2020;20(1):166.
52. Pan Y-J, Lin T-L, Chen C-T, Chen Y-Y, Hsieh P-F, Hsu C-R, et al. Genetic analysis of capsular polysaccharide synthesis gene clusters in 79 capsular types of *Klebsiella* spp. Scientific Reports. 2015;5(1):15573.
53. Domenico P, Salo RJ, Cross AS, Cunha BA. Polysaccharide capsule-mediated resistance to opsonophagocytosis in *Klebsiella pneumoniae*. Infection and Immunity. 1994;62(10):4495-9.
54. Paczosa Michelle K, Mecsas J. *Klebsiella pneumoniae*: Going on the Offense with a Strong Defense. Microbiology and Molecular Biology Reviews. 2016;80(3):629-61.
55. Ernst CM, Braxton JR, Rodriguez-Osorio CA, Zagieboylo AP, Li L, Pironti A, et al. Adaptive evolution of virulence and persistence in carbapenem-resistant *Klebsiella pneumoniae*. Nature Medicine. 2020;26(5):705-11.
56. Villa L, Feudi C, Fortini D, Brisse S, Passet V, Bonura C, et al. Diversity, virulence, and antimicrobial resistance of the KPC-producing *Klebsiella pneumoniae* ST307 clone. Microbial Genomics. 2017;3(4).
57. McGreal EP, Hearne K, Spiller OB. Off to a slow start: Under-development of the complement system in term newborns is more substantial following premature birth. Immunobiology. 2012;217(2):176-86.
58. Pasteur I. PubMLST Klebsiella isolate record #3292: Institut Pasteur; 2025 [Available from: https://bigsdb.pasteur.fr/cgi-bin/bigsdb/bigsdb.pl?page=info&db=pubmlst_klebsiella_isolates&id=3292].
59. Rodrigues C, Desai S, Passet V, Gajjar D, Brisse S. Genomic evolution of the globally disseminated multidrug-resistant *Klebsiella pneumoniae* clonal group 147. Microbial Genomics. 2022;8(1).
60. Peirano G, Chen L, Kreiswirth Barry N, Pitout Johann DD. Emerging Antimicrobial-Resistant High-Risk *Klebsiella pneumoniae* Clones ST307 and ST147. Antimicrobial Agents and Chemotherapy. 2020;64(10):10.1128/aac.01148-20.
61. Bialek-Davenet S, Criscuolo A, Ailloud F, Passet V, Jones L, Delannoy-Vieillard A-S, et al. Genomic Definition of Hypervirulent and Multidrug-Resistant *Klebsiella pneumoniae* Clonal Groups. Emerging Infectious Disease journal. 2014;20(11):1812.
62. Lee MY, Ko KS, Kang C-I, Chung DR, Peck KR, Song J-H. High prevalence of CTX-M-15-producing *Klebsiella pneumoniae* isolates in Asian countries: diverse clones and clonal dissemination. International Journal of Antimicrobial Agents. 2011;38(2):160-3.

63. Kuitunen I, Kekki M, Renko M. Intrapartum azithromycin to prevent maternal and neonatal sepsis and deaths: A systematic review with meta-analysis. BJOG: An International Journal of Obstetrics & Gynaecology. 2024;131(3):246-55.
64. Tapiainen T, Koivusaari P, Brinkac L, Lorenzi HA, Salo J, Renko M, et al. Impact of intrapartum and postnatal antibiotics on the gut microbiome and emergence of antimicrobial resistance in infants. Scientific Reports. 2019;9(1):10635.
65. Nogacka A, Salazar N, Suárez M, Milani C, Arboleya S, Solís G, et al. Impact of intrapartum antimicrobial prophylaxis upon the intestinal microbiota and the prevalence of antibiotic resistance genes in vaginally delivered full-term neonates. Microbiome. 2017;5(1):93.
66. Getanda P, Jagne I, Bognini JD, Camara B, Sanyang B, Darboe S, et al. Impact of Intrapartum Azithromycin on the Carriage and Antibiotic Resistance of *Escherichia coli* and *Klebsiella pneumoniae* in Mothers and Their Newborns: A Substudy of a Randomized, Double-Blind Trial Conducted in The Gambia and Burkina Faso. Clinical Infectious Diseases. 2024;79(6):1338-45.
67. Turta O, Selma-Royo M, Kumar H, Collado MC, Isolauri E, Salminen S, et al. Maternal Intrapartum Antibiotic Treatment and Gut Microbiota Development in Healthy Term Infants. Neonatology. 2021;119(1):93-102.
68. Mudenda W, Chikatula E, Chambula E, Mwanashimbala B, Chikuta M, Masaninga F, et al. Prescribing Patterns and Medicine Use at the University Teaching Hospital, Lusaka, Zambia. Medical Journal of Zambia. 2016;43:94-102.
69. Mudenda S, Chomba M, Chabalenge B, Hikaambo C, Banda M, Daka V, et al. Antibiotic Prescribing Patterns in Adult Patients According to the WHO AWaRe Classification: A Multi-Facility Cross-Sectional Study in Primary Healthcare Hospitals in Lusaka, Zambia. Pharmacology & Pharmacy. 2022;13:379-92.
70. Shawa M, Paudel A, Chambaro H, Kamboyi H, Nakazwe R, Alutuli L, et al. Trends, patterns and relationship of antimicrobial use and resistance in bacterial isolates tested between 2015–2020 in a national referral hospital of Zambia. PLOS ONE. 2024;19(4):e0302053.
71. Johnson J, Akinboyo IC, Schaffzin JK. Infection Prevention in the Neonatal Intensive Care Unit. Clinics in Perinatology. 2021;48(2):413-29.
72. Weinshel K, Dramowski A, Hajdu Á, Jacob S, Khanal B, Zoltán M, et al. Gap Analysis of Infection Control Practices in Low- and Middle-Income Countries. Infection Control & Hospital Epidemiology. 2015;36(10):1208-14.
73. Nakibuuka V, Nampijja J, Ajigbotosho SO, Edwards EM, Ehret DEY, Stevenson AG, et al. Resources to support infection prevention and control in African neonatal units. JOURNAL OF AFRICAN NEONATOLOGY. 2025;3(3):78 - 84.
74. Vuotto C, Longo F, Pascolini C, Donelli G, Balice MP, Libori MF, et al. Biofilm formation and antibiotic resistance in *Klebsiella pneumoniae* urinary strains. Journal of Applied Microbiology. 2017;123(4):1003-18.
75. Vock I, Tschudin-Sutter S. Persisting intrahospital transmission of multidrug-resistant *Klebsiella pneumoniae* and challenges for infection control. Infection Control & Hospital Epidemiology. 2019;40(8):904-9.
76. Zaidi AKM, Huskins WC, Thaver D, Bhutta ZA, Abbas Z, Goldmann DA. Hospital-acquired neonatal infections in developing countries. The Lancet. 2005;365(9465):1175-88.

Author contributions

Conceptualization: KEH, DHH, SEC
Formal analysis: LTP, KEH
Data Curation: MB
Funding Acquisition: KEH, DHH, SEC
Investigation: MB, MK, SM, LM, JCLM, CLM, JMT, FNE, EFN
Resources: DHH, SEC
Visualization: LTP, KEH
Writing – original draft: LTP, KEH
Writing – review & editing: All authors

Financial Disclosure Statement

The SPINZ study was funded by the Thrasher Research Fund [https://www.thrasherresearch.org/] (grant #12036 to DHH). Support for the sequencing and analysis of *K. pneumoniae* was provided by the Gates Foundation [https://www.gatesfoundation.org/] (INV-005691 to DHH, INV069410 and INV077266 to KEH). The study was designed, analyzed and implemented by the authors. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The conclusions and opinions expressed in this work are those of the author(s) alone and shall not be attributed to the funders. Under the grant conditions of the Gates Foundation, a Creative Commons Attribution 4.0 License has already been assigned to the Author Accepted Manuscript version that might arise from this submission. Please note works submitted as a preprint have not undergone a peer review process.


ST307
ST983
ST101
ST147
ST1119
ST2004
ST5856
ST985
ST15
Other
Aminoglycosides
Bla
Bla ESBL
Carbapenemase
Macrolides
Phenicol
Quinolone
Rifampicin
Sulfonamide
Tetracycline
Trimethoprim
Yersiniabactin
aac(3)-IIa
aac(3)-IId
aac(6')-Ib-cr
aac(6')-Ib'
aadA
aadA1
aadA16
aadA2
aph3-Ia
strA
strB
bla-LAP-2
bla-OXA-1
bla-TEM-1
bla-TEM-1D
bla-CTX-M-14
bla-CTX-M-15
bla-TEM-116
bla-NDM-5
mphA
mrx
catA1
catII-2
qnrB1
qnrB6
qnrB19
qnrS1
arr-3
sul1
sul2
tet(A)
tet(D)
dfrA1
dfrA12
dfrA14
dfrA15
dfrA27
yersiniabactin

A


ST985
ST983
ST307
ST2004
ST15
ST147
ST101
Other
0
20
40
60
Study week
n
5
10
15
20

B


60
40
20
0
25
42
63
32
24
22
20
14
18
5
6
20
18
4
1
10
1
3
5
7
9
11
13
15
17
Study month
Other
ST101
ST147
ST15
ST2004
ST307
ST983
ST985


A
Baseline
ST147 1
ST2004 1
ST307 1
ST307 2
ST307 3
ST985 1
Count
Inborn
Outborn
Unknown
B
Post-implementation
ST101 2
ST15 1
ST2004 2
ST307 4
ST307 5
ST983 1
Birth location
Onset category
Unknown
Rapid
Delayed


ST307
0
25
50
75
aac(3)-IIa
aac(6')-Ib-cr
aadA1
aadA2
aph3-Ia
bla-CTX-M-15
dfrA1
dfrA12
dfrA14
mphA
mrx
sul1
sul2
yersiniabactin
Birth location
Onset category
0
8
16
24
32
40
48
56
64
72
Drug class
Aminoglycosides
Bla ESBL
Macrolides
Sulfonamide
Trimethoprim
Yersiniabactin
Metadata
Inborn
Outborn
Rapid-onset
Delayed-onset
Unknown
Cluster number
1
2
3
4
5
Missing data
NC
ST101
0
100
200
300
400
500
aac(3)-IIa
aac(3)-IId
aac(6')-Ib-cr
aph3-Ia
bla-CTX-M-14
bla-CTX-M-15
dfrA1
dfrA14
mphA
mrx
sul1
sul2
yersiniabactin
Birth location
Onset category
0
8
16
24
32
40
48
56
64
72
ST2004
0
1
2
3
aac(6')-Ib-cr
aadA2
aph3-Ia
bla-CTX-M-15
dfrA12
dfrA14
sul2
Birth location
Onset category
0
8
16
24
32
40
48
56
64
72
Acquired resistance genes
Metadata
Study week


A
K-locus
Percentage (%)
100
75
50
25
0
87.1
9.0
3.6
43.8
3.6
24.7
2.2
0.0
1.8
5.6
1.8
0.0
0.0
4.5
0.0
12.4
KL102 (Capsule null)
K23
KL102
K39
K17
K64
K54
KL127
B
O-locus
Percentage (%)
90
60
30
0
96.4
82.0
3.6
5.6
0.0
12.4
OL2a.2
OL2a.1
OL13
C
Mean number of acquired AMR resistance genes
Mean
4
3
2
1
0
Aminoglycosides
Penicillins
Carbapenems
3rd generation cephalosporins
Fluoroquinolones
Macrolides
Phenicols
Rifampicin
Sulfonamides
Tetracyclines
Trimethoprim
Timepoint
Baseline
Post-implementation